Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Syndax Pharmaceuticals Inc SNDX

Healthcare Biotechnology
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing pipeline of cancer therapies. Its product candidates include revumenib, and axatilimab. It is developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute... see more

Recent & Breaking News (NDAQ:SNDX)

Syndax Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences

PR Newswire March 5, 2018

Syndax to Announce Fourth Quarter and Year-end 2017 Financial Results and Host Conference Call and Webcast on March 5, 2018

PR Newswire February 26, 2018

Syndax Announces Presentations at the 2018 American Association for Cancer Research Annual Meeting

PR Newswire February 22, 2018

10 Stocks Moving In Monday's After-Hours Session

Benzinga.com  February 5, 2018

Syndax Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca

PR Newswire February 1, 2018

Syndax Pharmaceuticals Announces Clinical Collaboration to Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast Cancer

PR Newswire January 10, 2018

Syndax Pharmaceuticals Announces Presentation of Data from Immuno-oncology Clinical Trials at the Society for Immunotherapy of Cancer 32nd Annual Scientific Meeting

PR Newswire November 11, 2017

Syndax Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Clinical and Business Update

PR Newswire November 7, 2017

Syndax Pharmaceuticals Inc to Host Earnings Call

Accesswire November 7, 2017

Syndax to Present at the SITC 32nd Annual Scientific Meeting

PR Newswire November 7, 2017

Syndax to Announce Third Quarter 2017 Financial Results and Host Conference Call and Webcast on November 7, 2017

PR Newswire October 31, 2017

Syndax Announces $25 Million Registered Direct Offering of Common Stock

PR Newswire October 17, 2017

Syndax Expands Pipeline with Exclusive Worldwide License to Allergan's Portfolio of Menin-MLL Inhibitors

PR Newswire October 17, 2017

Syndax Announces Dosing of First Patient in Pivotal Trial of Entinostat for the Treatment of Advanced or Recurrent Breast Cancer in Japan by Partner Kyowa Hakko Kirin

PR Newswire October 5, 2017

Syndax Pharmaceuticals Announces Updated Presentation Time at the Cantor Fitzgerald Global Healthcare Conference

PR Newswire September 20, 2017

Syndax Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

PR Newswire August 30, 2017

Investor Network: Syndax Pharmaceuticals Inc to Host Earnings Call

Accesswire August 10, 2017

Syndax to Announce Second Quarter 2017 Financial Results and Host Conference Call and Webcast on August 10, 2017

PR Newswire August 3, 2017

Preclinical Results Support Entinostat's Role in Targeting the Tumor Microenvironment to Enhance Immune Checkpoint Therapy

PR Newswire July 11, 2017

Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance

Business Wire June 21, 2017